This clinical study is looking at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult
patients with advanced solid tumours. The main aims are to find out the maximum dose of
LY3143921 hydrate that can be given safely to patients, more about the potential side effects
and how they can be treated